;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • ACH-3102: Interim Phase II data

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Product: ACH-3102 Business: Infectious Molecular target: HCV NS5A protein Description: Pan-genotypic, second-generation HCV NS5A protein inhibitor …

    Published on 8/18/2014
  • AP26113: Additional Phase I/II data

    Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Cambridge, Mass. Product: AP26113 Business: Cancer Molecular target: Anaplastic lymphoma kinase (ALK); Epidermal growth factor receptor (EGFR) Description: Dual inhibitor of …

    Published on 8/18/2014
  • Asonep sphingomab: Interim Phase IIa data

    Lpath Inc. (NASDAQ:LPTN), San Diego, Calif. Product: Asonep sphingomab Business: Cancer Molecular target: Sphingosine 1-phosphate (S1P) receptor Description: Systemic formulation of a humanized mAb against sphingosine 1…

    Published on 8/18/2014
  • Binimetinib: Phase Ib data

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Binimetinib (MEK162) (formerly ARRY-162) Business: Cancer Molecular target: MEK Description: Oral MEK …

    Published on 8/18/2014
  • Binimetinib: Phase Ib/II data

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Binimetinib (MEK162) (formerly ARRY-162) Business: Cancer Molecular target: MEK Description: Oral MEK …

    Published on 8/18/2014
  • BIOD-531: Preliminary Phase IIa data

    Biodel Inc. (NASDAQ:BIOD), Danbury, Conn. Product: BIOD-531 Business: Endocrine/Metabolic Molecular target: NA Description: Ultra rapid-acting formulation of recombinant human insulin Indication: Treat Type II diabetes …

    Published on 8/18/2014
  • BYL719: Phase Ib data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: BYL719 Business: Cancer Molecular target: Phosphoinositide 3-kinase (PI3K) alpha Description: Phosphoinositide 3-kinase (PI3K) alpha inhibitor Indication: …

    Published on 8/18/2014
  • Canaglu canagliflozin: Phase III data

    Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Canaglu canagliflozin (Invokana) (TA-7284, JNJ-28431754) Business: Endocrine/Metabolic Molecular …

    Published on 8/18/2014
  • CHS-1420: Clinical trial data

    Coherus BioSciences Inc., Redwood City, Calif. Product: CHS-1420 Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: Biosimilar of adalimumab, a human mAb against tumor necrosis factor…

    Published on 8/18/2014
  • ENMD-2076: Phase II data

    CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Product: ENMD-2076 Business: Cancer Molecular target: Aurora kinase A (AURKA) (Aurora-A); Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2…

    Published on 8/18/2014
  • FBP vaccine: Preliminary Phase I data

    Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore. Product: FBP vaccine (GALE-301) Business: Cancer Molecular target: Folate binding protein-E39 (FBP) Description: Folate binding protein-E39 (FBP) vaccine Indication: …

    Published on 8/18/2014
  • Flex Product: Phase I data

    Flex Pharma Inc., Boston, Mass. Product: Flex Product Business: Neurology Molecular target: Transient receptor potential vanilloid 1 (TRPV1) (VR1) Description: Liquid dietary supplement comprising the naturally …

    Published on 8/18/2014
  • Kyprolis carfilzomib: Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: Kyprolis carfilzomib (PR-171, ONO-7057) Business: Cancer Molecular target: Proteasome Description: …

    Published on 8/18/2014
  • LEE011: Phase Ib/II data

    Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: LEE011 Business: Cancer Molecular target: Cyclin dependent kinase 4 (CDK4); Cyclin dependent kinase 6 (CDK6) …

    Published on 8/18/2014
  • Lesinurad: Phase III data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Lesinurad (RDEA594) Business: Endocrine/Metabolic Molecular target: Solute carrier family 22 organic anion urate transporter member 12 (SLC22A12) (URAT1) …

    Published on 8/18/2014
  • Lesinurad: Phase III data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Lesinurad (RDEA594) Business: Endocrine/Metabolic Molecular target: Solute carrier family 22 organic anion urate transporter member 12 (SLC22A12) (URAT1) …

    Published on 8/18/2014
  • Lesinurad: Phase III data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Lesinurad (RDEA594) Business: Endocrine/Metabolic Molecular target: Solute carrier family 22 organic anion urate transporter member 12 (SLC22A12) (URAT1) …

    Published on 8/18/2014
  • Obeticholic acid: Additional Phase II data

    Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), New York, N.Y. Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Obeticholic acid (OCA) (DSP-1747) (formerly INT-747, 6ECDCA) Business: Hepatic …

    Published on 8/18/2014
  • PF-05280586: Phase I/II data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: PF-05280586 Business: Autoimmune Molecular target: CD20 Description: Biosimilar of rituximab, a chimeric mAb against CD20 antigen Indication: Treat moderate to severe …

    Published on 8/18/2014
  • PF-06438179: Phase I data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: PF-06438179 Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: Biosimilar of infliximab, a chimeric mAb against tumor necrosis factor (…

    Published on 8/18/2014
  • R118: Development discontinued

    Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Product: R118 Business: Cardiovascular Molecular target: AMP-activated protein kinase (AMPK) Description: Activator ofAMP-activated protein kinase (…

    Published on 8/18/2014
  • R348: Development discontinued

    Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Product: R348 Business: Ophthalmic Molecular target: JAK kinase (JAK); Spleen tyrosine kinase (SYK) Description: Topical ophthalmic JAK kinase (JAK) …

    Published on 8/18/2014
  • Rayaldee: Phase III data

    Opko Health Inc. (NYSE:OPK; Tel Aviv:OPK), Miami, Fla. Product: Rayaldee (Rayaldy) (CTAP101) Business: Endocrine/Metabolic Molecular target: NA Description: Modified-release formulation of 25-hydroxyvitamin D Indication…

    Published on 8/18/2014
  • RM-493: Phase Ib data

    Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Rhythm Pharmaceuticals Inc., Boston, Mass. Product: RM-493 (formerly BIM 22493) Business: Endocrine/Metabolic Molecular target: Melanocortin 4 …

    Published on 8/18/2014
  • Selumetinib: Phase I data

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Selumetinib (ARRY-886, AZD6244) Business: Cancer Molecular target: MEK Description: Small molecule MEK …

    Published on 8/18/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993